- Clinical-stage gene editing company Editas Medicine (NASDAQ:EDIT) announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust.
- Under the
